If there is dilution, it's relatively low – evident by how much lower the volume is on red days versus green days. The fact the A/S was only doubled, compared to what most OTC companies do (triple, quadruple, or worse) says their intent isn't to debase the stock long term.
The incorporation of a subsidiary in Colorado, with plans to acquire a revenue-generating entity, implies the raising of the A/S and possible dilution is a means to an end. They'll potentially use those newly issued shares and/or funds generated from selling some for acquisition purposes.
I mean, let's be realistic here. How many OTC companies aren't diluting or haven't diluted at some point? It comes with the territory, when a company isn't as profitable as they'd like to be and needs capital to add potential value. As long as a company has a viable end to justify their means, potential dilution is far from the end of the road.
That said, Bayport has a viable end and is working on getting there.
BAYP
News 
Market Data 
Discover 
AI
